

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/234134 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 35/17* (2015.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/EP2022/062374

(22) International Filing Date:
06 May 2022 (06.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/ES2021/070316
06 May 2021 (06.05.2021) ES

(71) Applicants: **INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS)** [ES/ES]; C/ Rosselló, 149-153, 08036 Barcelona (ES). **HOSPITAL CLÍNIC DE BARCELONA** [ES/ES]; C/ Villarroel 170, 08036 Barcelona (ES). **UNIVERSITAT DE BARCELONA** [ES/ES]; Centre de Patents de la UB, Baldiri Reixac 4 - Torre D, 08028 Barcelona (ES).

(72) Inventors: **JUAN OTERO, Manel**; Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 Barcelona (ES). **URBANO ISPIZUA, Álvaro**; Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 Barcelona (ES). **PASCAL CAPDEVILA, Mariona**; Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 Barcelona (ES). **YAGÜE RIBES, Jordi**; Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 Barcelona (ES). **DELGADO GONZÁLEZ, Julio**; Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 Barcelona (ES). **ESTEVE REYNER, Jordi**; Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 Barcelona (ES).

(74) Agent: **HOFFMANN EITLE S.L.U.**; Paseo de la Castellana 140, 3ª Planta, Edificio Lima, 28046 Madrid (ES).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/234134 A1

(54) Title: CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

(57) Abstract: The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.